This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by IGUCHI, H. Articles by ABE, M. Search for Related Content PubMed PubMed Citation Articles by IGUCHI, H. Articles by ABE, M.

Somatostatin- Secreting Islet Cell Tumor (Somatostatinoma): Suppression of Growth Hormone (GH) Release Induced by GH-Releasing Hormone

Departments of Biochemistry (H.I., M.A.), Gastroenterology (Internal Medicine; (S.K., H. W., Y.H.), Pathology (I.H.), and Gastroenterology (Surgery; Y.S.), National Kyushu Cancer Center Fukuoka 815, Japan
Gastroenterology (Surgery; Y.S.), National Kyushu Cancer Center Fukuoka 815, Japan

Address requests for reprints to: Dr. Haruo Iguchi; Department of Biochemistry, National Kyushu Cancer Center, 3-1-1 Notame, Minami-Ku, Fukuoka 815, Japan.

A patient with a somatostatin (SRIH)-secreting islet cell tumor, whose only symptoms were dyspepsia and anemia, is described. The diagnosis of somatostatinoma was based on high plasma SRIH concentrations and immunocytochemical findings. The pancreatic exocrine response to secretin was decreased, whereas the insulin and/or glucagon responses to glucose and arginine were normal. Although the basal plasma GH concentration was normal, the plasma GH response to GHRH was subnormal. Gel permeation chromatography studies indicated that SRIH-14 was the predominant form of SRIH in plasma as well as in tumor tissue.

Received November 6, 1987.